51 Results

People

  1. Hellmann
    Hellmann
  2. Rizvi
    Rizvi
  3. Wolchok
    Wolchok
  4. Merghoub
    Merghoub
  5. Plodkowski
    Plodkowski
  6. Rudin
    Rudin
  7. Schoenfeld
    Schoenfeld
  8. Egger
    Egger
  9. Postow
    Postow
  10. Arbour
    Arbour

Groups

  1. Department of Medicine (51)
  2. Solid Tumor Oncology Division (51)
  3. Thoracic Oncology (51)
  4. Melanoma and Immunotherapeutics Service (18)
  5. GSK Faculty (16)
  6. Radiology, Department of (11)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  8. Epidemiology and Biostatistics (10)
  9. Body Imaging Service (9)
  10. Hematologic Malignancies, Division of (9)
  1. "immunotherapy"
  2. "Matthew Hellmann"
Formats
  1. Journal Article (40)
  2. Meeting Abstract (6)
  3. Guidelines (2)
  4. Review (2)
  5. Editorial (1)
Groups
  1. Department of Medicine (51)
  2. Solid Tumor Oncology Division (51)
  3. Thoracic Oncology (51)
  4. Melanoma and Immunotherapeutics Service (18)
  5. GSK Faculty (16)
  6. Radiology, Department of (11)

More Groups

People
  1. Matthew Hellmann (51)
  2. Hira Rizvi (17)
  3. Jedd Wolchok (10)
  4. Taha Merghoub (9)
  5. Andrew Plodkowski (8)
  6. Adam Schoenfeld (7)

More People

Years
  1. 2024 (1)
  2. 2023 (4)
  3. 2022 (7)
  4. 2021 (7)
  5. 2020 (8)
  6. 2019 (4)

More Years

Publications
  1. Journal of Thoracic Oncology (11)
  2. Annals of Oncology (8)
  3. Journal for ImmunoTherapy of Cancer (7)
  4. Cancer Cell (5)
  5. Cell (5)
  6. European Journal of Cancer (3)

More Publications

Publishers
  1. Elsevier Inc. (14)
  2. Cell Press (11)
  3. Oxford University Press (9)
  4. Biomed Central Ltd (7)
  5. Nature Publishing Group (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (51)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
    Journal Article

    Memon, D.; Schoenfeld, A. J.; Ye, D.; Fromm, G.; Rizvi, H.; Zhang, X.; Keddar, M. R.; Mathew, D.; Yoo, K. J.; Qiu, J.; more...
    Cancer Cell (2024)

    Fulltext@MSK | Save
  • Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer
    Journal Article

    Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation
    Journal Article

    Rudin, C. M.; Balli, D.; Lai, W. V.; Richards, A. L.; Nguyen, E.; Egger, J. V.; Choudhury, N. J.; Sen, T.; Chow, A.; Poirier, J. T.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
    Guidelines

    Rizvi, N.; Ademuyiwa, F. O.; Cao, Z. A.; Chen, H. X.; Ferris, R. L.; Goldberg, S. B.; Hellmann, M. D.; Mehra, R.; Rhee, I.; Park, J. C.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • The ectonucleotidase CD39 identifies tumor-reactive CD8(+) T cells predictive of immune checkpoint blockade efficacy in human lung cancer
    Journal Article

    Chow, A.; Uddin, F. Z.; Liu, M.; Dobrin, A.; Nabet, B. Y.; Mangarin, L.; Lavin, Y.; Rizvi, H.; Tischfield, S. E.; Quintanal-Villalonga, A.; more...
    Immunity (2023)

    Fulltext@MSK | Save
  • Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer
    Journal Article

    Schoenfeld, A. J.; Rizvi, H. A.; Memon, D.; Shaverdian, N.; Bott, M. J.; Sauter, J. L.; Tsai, C. J.; Lihm, J.; Hoyos, D.; Plodkowski, A. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
    Guidelines

    Govindan, R.; Aggarwal, C.; Antonia, S. J.; Davies, M.; Dubinett, S. M.; Ferris, A.; Forde, P. M.; Garon, E. B.; Goldberg, S. B.; Hassan, R.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
    Journal Article

    Lopez de Rodas, M.; Nagineni, V.; Ravi, A.; Datar, I. J.; Mino-Kenudson, M.; Corredor, G.; Barrera, C.; Behlman, L.; Rimm, D. L.; Herbst, R. S.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Fundamental immune–oncogenicity trade-offs define driver mutation fitness
    Journal Article

    Hoyos, D.; Zappasodi, R.; Schulze, I.; Sethna, Z.; de Andrade, K. C.; Bajorin, D. F.; Bandlamudi, C.; Callahan, M. K.; Funt, S. A.; Hadrup, S. R.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: A phase I first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody
    Journal Article

    Farwell, M. D.; Gamache, R. F.; Babazada, H.; Hellmann, M. D.; Harding, J. J.; Korn, R.; Mascioni, A.; Le, W.; Wilson, I.; Gordon, M. S.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save